BOLD
NASDAQBoundless Bio Inc.
Price$2.48+0.03 (+1.22%)
02:00 PM07:45 PM
News · 26 weeks40+180%
2026-01-182026-07-12
Mix2490d
- Insider12(50%)
- SEC Filings7(29%)
- Other4(17%)
- Earnings1(4%)
Latest news
25 items- INSIDERLarge owner Tang Kevin bought $155,646 worth of shares (63,969 units at $2.43) (SEC Form 4)4 - Boundless Bio, Inc. (0001782303) (Issuer)
- INSIDERLarge owner Tang Kevin bought $222,070 worth of shares (91,585 units at $2.42) (SEC Form 4)4 - Boundless Bio, Inc. (0001782303) (Issuer)
- INSIDERLarge owner Tang Kevin bought $141,865 worth of shares (57,210 units at $2.48) (SEC Form 4)4 - Boundless Bio, Inc. (0001782303) (Issuer)
- INSIDERLarge owner Crandell Keith exercised 16,000 shares at a strike of $1.03 and sold $39,840 worth of shares (16,000 units at $2.49) (SEC Form 4)4 - Boundless Bio, Inc. (0001782303) (Issuer)
- INSIDERLarge owner Arch Venture Fund Ix, L.P. exercised 16,000 shares at a strike of $1.03 and sold $39,840 worth of shares (16,000 units at $2.49) (SEC Form 4)4 - Boundless Bio, Inc. (0001782303) (Issuer)
- INSIDERLarge owner Tang Kevin bought $268,880 worth of shares (107,463 units at $2.50) (SEC Form 4)4 - Boundless Bio, Inc. (0001782303) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Boundless Bio Inc.SCHEDULE 13G - Boundless Bio, Inc. (0001782303) (Subject)
- INSIDERLarge owner Tang Kevin bought $714,768 worth of shares (286,333 units at $2.50) (SEC Form 4)4 - Boundless Bio, Inc. (0001782303) (Issuer)
- INSIDERNew insider Tang Kevin claimed ownership of 2,247,512 shares (SEC Form 3)3 - Boundless Bio, Inc. (0001782303) (Issuer)
- PRThese Emerging Companies Are Racing Toward Major CatalystsDENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points. NeOnc Technologies Approaches Major Clinical Catalyst NeOnc Technologies (NASDAQ:NTHI) has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Pha
- SECSEC Form 425 filed by Boundless Bio Inc.425 - Boundless Bio, Inc. (0001782303) (Subject)
- SECBoundless Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure8-K - Boundless Bio, Inc. (0001782303) (Filer)
- PRBoundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private PlacementCombined company to operate as Serapha Bio and to advance Serapha’s potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha’s lead program SERP-01 targets the SERPINA1 E342K (PiZZ) mutation, with proof-of-concept data demonstrating restoration of serum AAT to normal levels Concurrent $230 million private placement co-led by RTW Investments and RA Capital Management, with participation from syndicate of top healthcare investors and mutual funds Companies to hold joint webcast on Tuesday, June 23, 2026 at 8:30 a.m. ET SAN DIEGO and NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Boundless Bio, Inc. (NASDAQ:BOLD) and Serapha Bio, Inc., a privately held
- PRNext-Generation DNA Repair Therapies Open New Frontiers in OncologyAUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030. New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Li
- SECBoundless Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Boundless Bio, Inc. (0001782303) (Filer)
- INSIDERSEC Form 4 filed by Director Whiting Nancy4 - Boundless Bio, Inc. (0001782303) (Issuer)
- INSIDERSEC Form 4 filed by Director Lim Jonathan E4 - Boundless Bio, Inc. (0001782303) (Issuer)
- INSIDERSEC Form 4 filed by Director Christensen James4 - Boundless Bio, Inc. (0001782303) (Issuer)
- INSIDERSEC Form 4 filed by Director Lew Jennifer4 - Boundless Bio, Inc. (0001782303) (Issuer)
- SECSEC Form 10-Q filed by Boundless Bio Inc.10-Q - Boundless Bio, Inc. (0001782303) (Filer)
- SECBoundless Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Boundless Bio, Inc. (0001782303) (Filer)
- PRBoundless Bio Reports First Quarter 2026 Financial Results and Business HighlightsEnrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026. "We are encouraged by the progress of the KOMODO-1 trial," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. "We continue to exp
- SECSEC Form DEFA14A filed by Boundless Bio Inc.DEFA14A - Boundless Bio, Inc. (0001782303) (Filer)
- SECSEC Form DEF 14A filed by Boundless Bio Inc.DEF 14A - Boundless Bio, Inc. (0001782303) (Filer)
- PRBoundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual MeetingSAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical data supporting its lead ecDNA-directed therapy (ecDTx), BBI-940, at the American Association for Cancer Research (AACR) Annual Meeting 2026. Boundless has identified a novel kinesin target ("Kinesin") essential to ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940, a potentially first-in-class, oral, and selective Kinesin degrader, is currently being evaluated in th
BOLD FAQ
6 questionsWhere does BOLD stock trade?
Boundless Bio Inc. (BOLD) is listed on NASDAQ.What sector and industry is BOLD in?
Boundless Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Boundless Bio Inc. go public?
Boundless Bio Inc. (BOLD) completed its IPO in 2024.What are analysts saying about BOLD?
Boundless Bio Inc. has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $500.00 price target on 2025-06-02. Recent price targets range from $300.00 to $500.00.What companies are similar to BOLD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare BOLD side-by-side with any of them on Quantisnow.How can I track BOLD on Quantisnow?
Quantisnow aggregates Boundless Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BOLD to receive live email and push alerts on every new disclosure.